The Impact of Sodium-Glucose Co-Transporter-2 Inhibitors on Weight Loss in Obesity
SGLT-2 inhibitors in Obesity
Abstract views: 211
/ 
PDF downloads: 100
DOI:
https://doi.org/10.5281/zenodo.8135541Keywords:
Obesity, SGLT-2 inhibitors, weight loss, diabetesAbstract
Obesity is a chronic medical condition characterized by excessive body fat accumulation, posing health risks. Obesity is influenced by genetic, environmental, behavioral, and socioeconomic factors, emphasizing its complexity. It is associated with numerous comorbidities, including type 2 diabetes, cardiovascular diseases, respiratory disorders, and certain cancers. Obesity management involves a multidisciplinary approach, including lifestyle modifications, behavioral therapy, pharmacotherapy, and bariatric surgery in severe cases. Studies highlight the weight loss effects of various sodium-glucose co-transporter 2 inhibitors (SGLT-2i) such as canagliflozin, dapagliflozin, and empagliflozin, in diabetic and non-diabetic obese individuals. Modest reductions in body weight have been observed, supporting the use of SGLT-2i as a weight management option. SGLT-2i, initially used for diabetes, has demonstrated additional benefits for managing obesity and related metabolic conditions. Clinical trials and real-world evidence consistently show significant weight loss in individuals treated with SGLT-2i, independent of their glucose-lowering properties. The weight loss observed is smaller than expected due to adaptive mechanisms that increase energy intake to counterbalance the loss. Combining SGLT-2i with appetite-suppressing drugs, such as GLP-1 analogs, may enhance weight reduction. However, further research is needed to optimize the weight-reducing effects and explore combination therapies. Despite these limitations, SGLT-2i remains valuable in managing obesity and offers benefits beyond glycemic control.
References
Apovian CM. Obesity: definition, comorbidities, causes, and burden. Am J Manag Care. 2016 Jun;22(7 Suppl):s176-85. PMID: 27356115.
McLaren L. Socioeconomic status and obesity. Epidemiol Rev. 2007;29:29-48. doi: 10.1093/epirev/mxm001. Epub 2007 May 2. PMID: 17478442.
Ling C, Rönn T. Epigenetics in Human Obesity and Type 2 Diabetes. Cell Metab. 2019 May 7;29(5):1028-1044. doi: 10.1016/j.cmet.2019.03.009. Epub 2019 Apr 11. PMID: 30982733; PMCID: PMC6509280.
Ni L, Yuan C, Chen G, Zhang C, Wu X. SGLT2i: beyond the glucose-lowering effect. Cardiovasc Diabetol. 2020 Jun 26;19(1):98. doi: 10.1186/s12933-020-01071-y. PMID: 32590982; PMCID: PMC7320582.
Palanca A, van Nes F, Pardo F, Ampudia Blasco FJ, Mathieu C. Real-world Evidence of Efficacy and Safety of SGLT2 Inhibitors as Adjunctive Therapy in Adults With Type 1 Diabetes: A European Two-Center Experience. Diabetes Care. 2022 Mar 1;45(3):650-658. doi: 10.2337/dc21-1584. PMID: 35061022.
Gronda E, Lopaschuk GD, Arduini A, Santoro A, Benincasa G, Palazzuoli A, Gabrielli D, Napoli C. Mechanisms of action of SGLT2 inhibitors and their beneficial effects on the cardiorenal axis. Can J Physiol Pharmacol. 2022 Feb;100(2):93-106. doi: 10.1139/cjpp-2021-0399. PMID: 35112597.
Bolinder J, Ljunggren Ö, Johansson L, Wilding J, Langkilde AM, Sjöström CD, Sugg J, Parikh S. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014 Feb;16(2):159-69. doi: 10.1111/dom.12189. Epub 2013 Aug 29. PMID: 23906445.
Bays HE, Weinstein R, Law G, Canovatchel W. Canagliflozin: effects in overweight and obese subjects without diabetes mellitus. Obesity (Silver Spring). 2014 Apr;22(4):1042-9. doi: 10.1002/oby.20663. Epub 2013 Dec 9. PMID: 24227660; PMCID: PMC4285787.
He YL, Haynes W, Meyers CD, Amer A, Zhang Y, Mahling P, Mendonza AE, Ma S, Chutkow W, Bachman E. The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes. Diabetes Obes Metab. 2019 Jun;21(6):1311-1321. doi: 10.1111/dom.13654. Epub 2019 Mar 15. PMID: 30724002.
Jensterle M, Rizzo M, Haluzík M, Janež A. Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review. Adv Ther. 2022 Jun;39(6):2452-2467. doi: 10.1007/s12325-022-02153-x. Epub 2022 May 3. PMID: 35503498; PMCID: PMC9063254.
Jepsen MM, Christensen MB. Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity. Expert Opin Emerg Drugs. 2021 Sep;26(3):231-243. doi: 10.1080/14728214.2021.1947240. Epub 2021 Jul 6. PMID: 34176426.
Hui F, Zhang Y, Ren T, Li X, Zhao M, Zhao Q. Role of metformin in overweight and obese people without diabetes: a systematic review and network meta-analysis. Eur J Clin Pharmacol. 2019 Apr;75(4):437-450. doi: 10.1007/s00228-018-2593-3. Epub 2018 Dec 3. PMID: 30511328.
Yerevanian A, Soukas AA. Metformin: Mechanisms in Human Obesity and Weight Loss. Curr Obes Rep. 2019 Jun;8(2):156-164. doi: 10.1007/s13679-019-00335-3. PMID: 30874963; PMCID: PMC6520185.
Pratama KG, Tandarto K, Hengky A. WEIGHT LOSS EFFECT OF SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITORS IN PATIENTS WITH OBESITY WITHOUT DIABETES: A SYSTEMATIC REVIEW. Acta Endocrinol (Buchar). 2022 Apr-Jun;18(2):216-224. doi: 10.4183/aeb.2022.216. PMID: 36212248; PMCID: PMC9512389.
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17. PMID: 26378978.
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12. PMID: 28605608.
Furtado RHM, Raz I, Goodrich EL, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Aylward P, Dalby AJ, Dellborg M, Dimulescu D, Nicolau JC, Oude Ophuis AJM, Cahn A, Mosenzon O, Gause-Nilsson I, Langkilde AM, Sabatine MS, Wiviott SD. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. Circulation. 2022 May 24;145(21):1581-1591. doi: 10.1161/CIRCULATIONAHA.121.058103. Epub 2022 May 5. PMID: 35510542.
Sugiyama S, Jinnouchi H, Kurinami N, et al. Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes. J Atheroscler Thromb. 2018;25(6):467-476. doi:10.5551/jat.40873
Busko M. SGLT2 Inhibitors: Real-World Data Show Benefits Outweigh Risks. https://www.medscape.com/viewarticle/990323 March 31, 2023. Accessed date: May 18, 2023.
Liu XY, Zhang N, Chen R, Zhao JG, Yu P. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years. J Diabetes Complications. 2015 Nov-Dec;29(8):1295-303. doi: 10.1016/j.jdiacomp.2015.07.011. Epub 2015 Jul 21. PMID: 26365905.
Bays HE, Kozlovski P, Shao Q, Proot P, Keefe D. Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity. Obesity (Silver Spring). 2020 May;28(5):870-881. doi: 10.1002/oby.22764. Epub 2020 Mar 18. PMID: 32187881; PMCID: PMC7217021.
He YL, Haynes W, Meyers CD, Amer A, Zhang Y, Mahling P, Mendonza AE, Ma S, Chutkow W, Bachman E. The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes. Diabetes Obes Metab. 2019 Jun;21(6):1311-1321. doi: 10.1111/dom.13654. Epub 2019 Mar 15. PMID: 30724002.
Hollander P, Bays HE, Rosenstock J, Frustaci ME, Fung A, Vercruysse F, Erondu N. Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial. Diabetes Care. 2017 May;40(5):632-639. doi: 10.2337/dc16-2427. Epub 2017 Mar 13. PMID: 28289041.
Lundkvist P, Sjöström CD, Amini S, Pereira MJ, Johnsson E, Eriksson JW. Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes. Diabetes Obes Metab. 2017 Jan;19(1):49-60. doi: 10.1111/dom.12779. Epub 2016 Sep 26. PMID: 27550386; PMCID: PMC5215525.
Ramírez-Rodríguez AM, González-Ortiz M, Martínez-Abundis E. Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients with Prediabetes. Exp Clin Endocrinol Diabetes. 2020 Aug;128(8):506-511. doi: 10.1055/a-0664-7583. Epub 2018 Aug 27. PMID: 30149417.
Vallianou NG, Tsilingiris D, Kounatidis D, Lempesis IG, Karampela I, Dalamaga M. Sodium glucose cotransporter 2 inhibitors in obesity and associated cardiometabolic disorders: where do we stand? Pol Arch Intern Med. 2022 Oct 21;132(10):16342. doi: 10.20452/pamw.16342. Epub 2022 Sep 12. PMID: 36094176.
Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall KD, Ferrannini E. Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care. 2015 Sep;38(9):1730-5. doi: 10.2337/dc15-0355. Epub 2015 Jul 15. PMID: 26180105; PMCID: PMC4542276.
Cheong AJY, Teo YN, Teo YH, Syn NL, Ong HT, Ting AZH, Chia AZQ, Chong EY, Chan MY, Lee CH, Lim AYL, Kong WKF, Wong RCC, Chai P, Sia CH. SGLT inhibitors on weight and body mass: A meta-analysis of 116 randomized-controlled trials. Obesity (Silver Spring). 2022 Jan;30(1):117-128. doi: 10.1002/oby.23331. PMID: 34932882.
Zheng H, Liu M, Li S, Shi Q, Zhang S, Zhou Y, Su N. Sodium-Glucose Co-Transporter-2 Inhibitors in Non-Diabetic Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne). 2021 Aug 16; 12:706914. doi: 10.3389/fendo.2021.706914. PMID: 34484120; PMCID: PMC8415407.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Semahat Karahisar Şirali, Ramazan Öztürk
This work is licensed under a Creative Commons Attribution 4.0 International License.
The journal is licensed under a 